scholarly journals Yes-Associated Protein 1 as a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Luo Zhang ◽  
Xing Song ◽  
Xiaodong Li ◽  
Changping Wu ◽  
Jingting Jiang
Keyword(s):  
Gastrointestinal Cancer ◽  
Poor Prognosis ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Hippo Pathway ◽  
Cochrane Library ◽  
Prognostic Effect ◽  
Hazard Ratios ◽  
The Relationship

Background. Yes-associated protein 1 (YAP1) is an effector of Hippo pathway, which plays a significant role in cell proliferation and tumor progression. The relationship between YAP1 and gastrointestinal cancer has been explored in many previous studies. We conducted a meta-analysis to explore the prognostic effect of YAP1 in patients with gastrointestinal cancer.Methods. A systematic search was performed through the PubMed, Web of Science, Embase, and Cochrane library databases to collect eligible studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the relationship between YAP1 expression and gastrointestinal cancer clinical outcomes.Results. A total of 2941 patients from 18 studies were enrolled. The results showed that elevated YAP1 expression predicted a poor prognosis in gastrointestinal cancer (HR = 1.56; 95% CI: 1.29-1.89;P< 0.001). Subgroup analyses indicated significant association between YAP1 overexpression and shorter OS of patients with esophageal squamous cell carcinoma (HR = 1.85; 95% CI: 1.25-2.73;P= 0.002), gastric cancer (HR = 1.41,95% CI: 1.02-1.95;P= 0.037), and colorectal cancer (pooled HR = 1.75; 95% CI: 1.42-2.15;P< 0.001). However, YAP1 expression did not affect DFS of patients with gastrointestinal cancer (pooled HR = 1.33; 95% CI: 0.95-1.88;P= 0.101).Conclusion. Elevated YAP1 expression in patients with gastrointestinal cancer might be related to shorter OS. YAP1 protein could serve as a potential predictor of poor prognosis in gastrointestinal cancer.

scholarly journals The prognostic utility and clinical outcomes of MNX1-AS1 expression in cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Juan Li ◽  
Wen Jin ◽  
Zhengyu Zhang ◽  
Jingjing Chu ◽  
Hui Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Clinical Outcomes ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
High Expression ◽  
Hazard Ratios ◽  
Prognostic Utility ◽  
The Relationship ◽  
Worse Prognosis

Abstract Background: Recently, emerging studies have identified that MNX1-AS1 highly expressed among variety of cancers and related with worse prognosis of cancer patients. The purpose of this study was to evaluate the relationship between MNX1-AS1 expression with clinical features and prognosis in different cancers. Methods: In this study, we searched the Web of Science, PubMed, CNKI, and Wanfang databases to find relevant studies of MNX1-AS1. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the prognostic and clinical significance of MNX1-AS1. Results: A total of 9 literatures were included in this study, including 882 cancer patients. The results showed that patients with increased MNX-AS1 expression were more likely to develop lymph node metastasis (OR = 5.616, 95%CI: 3.093 - 10.199, P = 0.000) and advanced TNM stage (OR = 4.625, 95%CI: 2.366-9.040, P = 0.000). Moreover, we demonstrated that patients with high expression of MNX1-AS1 had poor OS in different cancers (HR = 1.976, 95%CI: 1.653 - 2.361, P=0.000). In addition, patients with high expression of MNX1-AS1 suffer from worse prognosis in gastric cancer (HR = 2.385, 95% CI: 1.838 - 3.094, P = 0.000) and lung cancer (HR= 1.959, 95%CI: 1.353 - 2.835, P = 0.000). Conclusions: High MNX1-AS1 expression is significantly associated with unfavorable clinical outcomes and it has the potential to serve as a prognostic biomarker in cancer patients.

scholarly journals Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

2021 ◽  
Author(s):  
Weiwei Chen ◽  
Yuting Li ◽  
Liliangzi Guo ◽  
Chenxing Zhang ◽  
Shaohui Tang
Keyword(s):  
Meta Analysis ◽  
Clinical Stage ◽  
Predictive Marker ◽  
Clinicopathological Characteristics ◽  
Cochrane Library ◽  
Hazard Ratios ◽  
Non Coding Rna ◽  
The Relationship ◽  
Long Non Coding Rna

Background: Several studies have assessed the relationship between long non-coding RNA five prime to Xist (FTX) expression, clinicopathological features, and survival outcomes in cancer patients with conflicting results. This meta-analysis synthesized existing data to clarify the association between FTX with cancer prognosis.Methods: PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Eleven studies comprising 1,210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma were enrolled in this analysis. The meta-analysis showed that high FTX expression was significantly associated with several clinicopathological characteristics, including lymph node metastasis in patients with CRC, GC, HCC, and RCC, distant metastasis in patients with CRC, GC, HCC, and OSC, larger tumor size in patients with CRC, GC, HCC, RCC, and OSC, and subsequently TNM/clinical stage in patients with CRC, GC, HCC, OSC, and glioma. The pooled results from the survival analysis revealed a significant correlation between high FTX expression and shorter OS in patients with HCC, CRC, GC, OSC, and glioma. Further, FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions: FTX may be a potential oncogene, with high FTX expression being associated with a poorer prognosis in patients with CRC, HCC, OSC, and glioma

The prognostic value of long non-coding RNA PlncRNA-1 in patients with cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Lijun Lei ◽  
Lianbing Sheng ◽  
Lingyuan Wu ◽  
Jiaojing Liu ◽  
Bin Wei ◽  
...  
Keyword(s):  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Database Search ◽  
Clinical Prognosis ◽  
Non Coding Rna ◽  
Increased Risk ◽  
Cancer Types ◽  
The Relationship ◽  
Long Non Coding Rna

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.

scholarly journals Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

2020 ◽  
Author(s):  
Weiwei Chen ◽  
Yuting Li ◽  
Liliangzi Guo ◽  
Chenxing Zhang ◽  
Shaohui Tang
Keyword(s):  
Poor Prognosis ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Predictive Marker ◽  
Cochrane Library ◽  
Patients With Cancer ◽  
Hazard Ratios ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Abstract Background Several studies assessed the relationship between FTX expression level and clinicopathological features and survival outcomes in patients with cancer, but these results were conflicting. This meta-analysis aimed to synthesize existing data to clarify the association of FTX with prognosis of cancers. Methods Electronic databases of PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). Results In total, 11 studies compromising 1210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma, were enrolled in this analysis. The meta-analysis showed that high FTX expression was associated with lymph node metastasis, distant metastasis, tumor size and TNM/clinical stage. More importantly, the pooled results from survival analysis revealed that there was a significant correlation between high FTX expression and a shorter OS in patients with HCC, CRC, GC, OSC, and glioma, and that FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions FTX may be a potential oncogene, and high FTX expression be associated with a poor prognosis in patients with CRC, HCC, OSC, and glioma.

scholarly journals Association of the CYP17 (T-34C) Polymorphism and the Risk of Acne Vulgaris: A Meta-Analysis

2018 ◽  
Author(s):  
Mazaher Ramezani ◽  
Elisa Zavattaro ◽  
Masoud Sadeghi
Keyword(s):  
Web Of Science ◽  
Skin Diseases ◽  
Genetic Relationships ◽  
Meta Analysis ◽  
Acne Vulgaris ◽  
Cochrane Library ◽  
Asian Ethnicity ◽  
Common Skin ◽  
The Relationship ◽  
Review Manager

Acne vulgaris is one of the most common skin diseases and genetic relationships have been documented. The aim was to evaluate the association of CYP17 (T-34C) polymorphism related to the risk of acne in a meta-analysis study. The databases (Scopus, Web of Science, PubMed, and Cochrane Library) were searched until September 2018 to check the relationship between acne risk and CYP17 (T-34C) polymorphism and impact of this polymorphism on severity of acne. We used Review Manager 5.3 software to analyze the data using OR and 95% CI to check this relationship. Four studies were included and analyzed in the meta-analysis. The OR in analysis of C versus T in acne patients compared to the healthy controls was 1.42 (P=0.02), in CC vs. TT was 1.54 (P=0.04), in TC vs. TT was 1.46 (P=0.12), in TC + CC vs. TT was 1.55 (P=0.04), and in CC vs. TT + TC was 1.39 (P=0.06). There was no acne risk related to CYP17 (T-34C) in none of genetic models in Caucasian ethnicity, whereas in Asian ethnicity, there was higher acne risk related to CYP17 (T-34C) without heterogeneity. The results of the present meta-analysis showed the presence of C allele and CC genotype of CYP17 polymorphism can be risk factors for acne, mainly in the Asian ethnicity.

scholarly journals Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis

2021 ◽  
Author(s):  
MY Cynthia Stafford ◽  
Colin E Willoughby ◽  
Colum P Walsh ◽  
Declan J McKenna
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Disease Progression ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Risk Groups ◽  
Cochrane Library ◽  
Clinical Biomarker ◽  
Meta Analyses ◽  
The Relationship

Elevated levels of miR-21 expression are associated with many cancers, suggesting it may be a promising clinical biomarker. In prostate cancer (PCa), however, there is still no consensus about the usefulness of miR-21 as an indicator of disease progression. This systematic review and meta-analysis was conducted to investigate the value of miR-21 expression as a prognostic measurement in PCa patients. Medline (Ovid), EMBASE, Web of Science, Scopus and Cochrane Library databases were systematically searched for relevant publications between 2010 to 2021. Studies exploring the relationship between miR-21 expression, PCa prognosis and clinicopathological factors were selected for review. Those reporting hazard ratio (HR) and 95% confidence intervals (CIs) were subject to meta-analyses. Fixed-effect models were employed to calculated pooled HRs and 95% CIs. Risk of bias in each study was assessed using QUIPS tool. Certainty of evidence in each meta-analysis was assessed using GRADE guidelines. A total of 64 studies were included in the systematic review. Of these, 11 were eligible for inclusion in meta-analysis. Meta-analyses revealed that high miR-21 expression was associated with poor prognosis: HR=1.58 (95% CI=1.19-2.09) for biochemical recurrence, MODERATE certainty; HR=1.46 (95% CI=1.06-2.01) for death, VERY LOW certainty; and HR=1.26 (95% CI=0.70-2.27) for disease progression, VERY LOW certainty. Qualitative summary revealed elevated miR-21 expression was significantly positively associated with PCa stage, Gleason score and risk groups. This systematic review and meta-analysis suggests that elevated levels of miR-21 are associated with poor prognosis in PCa patients. miR-21 expression may therefore be a useful prognostic biomarker in this disease.

scholarly journals Prognostic and clinicopathological significance of YAP in Colorectal carcinoma: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Lu Dai ◽  
Xiao Jin ◽  
Jiayan Wang ◽  
Yilan Ma ◽  
Haihao Yan ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Great Influence ◽  
Tumor Location ◽  
Clinicopathological Features ◽  
Expression Level ◽  
Cochrane Library ◽  
Hazard Ratios ◽  
Clinicopathological Significance ◽  
Prediction Of Prognosis ◽  
The Relationship

Abstract Background: YAP is a protein encoded by the YAP gene in humans. Numerous studied showed that YAP expressed in colorecal carcinoma (CRC) and has a association with poor clinical outcomes. However, the association between YAP expression level with prognostic and clinicopathological features in CRC patients remains unclear. Therefore, we performed a meta-analysis to investigate the prognostics effect of YAP expression on CRC patients.Methods: A systematic search of the PubMed, Web of Science, Cochrane Library and Embase databases was conducted based on predefined selection criteria in April 26, 2020. The correlation between YAP expression level and survival outcomes or clinicopathological characteristic was analyzed by hazard ratios (HR) or odds ratios (OR) at 95% confdence intervals (CI).Results: 12 studies were included, with a total of 2286 CRC patients,in our meta-analysis.the results show the relationship between YAP expression level with overall survival (OS) in CRC patients HR (2.02, 95%CI 1.67-2.44 I2 =19.7% P= 0.25) . In addition to clinicpathological features, CRC patients with overexpression of YAP were tend to advanced TNM stage(OR:2.99, 95%CI 2.11-4.25, I2=0.0%, P=0.699), lymph node metastasis(OR:3.73, 95% CI 2.63-5.30, I2=4.8%, P=0.386), distant metastasis(OR:3.03, 95% CI 1.21-7.56, I2=65.3%, P=0.021), tumor invasion depth HR (2.82 95%CI 1.65-4.83 I2=0.0%, p=0.413), but have no associated with sex, tumor size, tumor location and tumor differentiation.Conclusion: The results of this meta-analysis show that high expression of YAP tended to have a worse progosis and have great influence on clinicpathological features. which means YAP may serve as a promising indicator in the prediction of prognosis and clinicopathological features in CRC patients.

scholarly journals The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis

2019 ◽  
Author(s):  
Sen Wang ◽  
Jia Wu ◽  
Junjun Wang
Keyword(s):  
Solid Tumors ◽  
Poor Prognosis ◽  
Web Of Science ◽  
Meta Analysis ◽  
Tumor Therapy ◽  
High Expression ◽  
The Poor ◽  
Tumor Prognosis ◽  
The Relationship ◽  
Rate Limiting

Abstract Background: Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme in the metabolism of tryptophan into kynurenine. It is considered to be an immunosuppressive molecule that plays an important role in the development of tumors. However, the relationship between IDO and solid tumor prognosis remains unclear. Herein, we retrieved relevant published literature and analyzed the relationship between IDO expression and prognosis in solid tumors.Methods: Studies related to IDO expression and tumor prognosis were retrieved using PMC, EMbase and web of science database. Overall survival (OS) and other data in each study were extracted. Hazard ratio (HR) was used for analysis and calculation, while heterogeneity and publication bias between studies were also analyzed.Results: A total of 29 studies were included in this meta-analysis. Overall, high expression of IDO was significantly associated with poor OS (HR 1.98, 95% CI 1.55–2.53) and TTP (HR 2.25 95% CI 1.58–3.22). Subgroup analysis suggested that the associations between IDO expression and poor OS were significant in the prospective studies without obvious heterogeneity.Conclusions: The high expression of IDO was significantly associated with the poor prognosis of solid tumors, suggesting that it can be used as a biomarker for tumor prognosis and as a potential target for tumor therapy.

scholarly journals ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yuqiang Zhang ◽  
Sufen Cao ◽  
Chunyu Zhuang ◽  
Jiacheng Chen ◽  
Xiaojing Chen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Web Of Science ◽  
Meta Analysis ◽  
Asian Population ◽  
Caucasian Population ◽  
Cochrane Library ◽  
Platinum Drugs ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
The Relationship

Abstract Objective To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. Methods Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software. Results A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found. Conclusion The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.

scholarly journals Adjuvant therapy for retroperitoneal sarcoma: a meta-analysis

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Xiangji Li ◽  
Tong Wu ◽  
Mengmeng Xiao ◽  
Shanshan Wu ◽  
Li Min ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Web Of Science ◽  
Meta Analysis ◽  
Evidence Base ◽  
Cochrane Library ◽  
Free Survival ◽  
Hazard Ratios ◽  
Promising Treatment ◽  
Retroperitoneal Sarcomas

Abstract Background Adjuvant therapy is a promising treatment to improve the prognosis of cancer patients, however, the evidence base driving recommendations for adjuvant radiotherapy (ART) or chemotherapy (ACT) in retroperitoneal sarcomas (RPS) primarily hinges on observational data. The aim of this study was to evaluate the effectiveness of adjuvant therapy in the management of RPS patients. Methods We searched PubMed, Web of Science, Embase, ASCO Abstracts, and Cochrane Library for comparative studies (until December 2020) of adjuvant therapy versus surgery alone. Data on the following endpoints were evaluated: overall survival (OS), local recurrence (LR), recurrence-free survival (RFS), and metastasis-free survival (MFS). Data were summarized as hazard ratios (HR) with 95% confidence intervals (CI). Risk of bias of studies was assessed with Begg’s and Egger’s tests. Results A total of 15 trials were eligible, including 9281 adjuvant therapy and 21,583 surgery alone cases (20 studies for OS, six studies for RFS, two studies for LR, and two studies for MFS). Meta-analysis showed that ART was associated with distinct advantages as compared to surgery alone, including a longer OS (HR = 0.80, P < 0.0001), a longer RFS (HR = 0.61, P = 0.0002), and a lower LR (HR = 0.31, P = 0.005). However, this meta-analysis failed to demonstrate a benefit of ACT for RPS patients, including OS (HR = 1.11, P = 0.19), RFS (HR = 1.30, P = 0.09) and MFS (HR = 0.69, P = 0.09). In the sensitivity analysis, ACT was associated with a worse OS (HR = 1.19, P = 0.0002). No evidence of publication bias was observed. Conclusions Overall, the quality of the evidence was moderate for most outcomes. The evidence supports that ART achieved a generally better outcome as compared to surgery alone.

Sign in / Sign up

Export Citation Format

Share Document